Story

Argenx Upgraded to Buy by UBS on $20 Billion Peak Sales Outlook for Vyvgart

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Argenx Upgraded to Buy by UBS on $20 Billion Peak Sales Outlook for Vyvgart
Text size
Background

UBS has upgraded Argenx (EBR:ARGX) to a 'Buy' rating and substantially increased its price target, citing a clearer path for the biopharmaceutical company's flagship drug, Vyvgart, to reach nearly $20 billion in peak sales.

Following the analyst action, shares of Argenx rose 2.8% in Brussels trading, as reported by Investing.com.

Analyst Lifts Rating and Target

In a note to clients on Wednesday, UBS raised its rating on Argenx to 'Buy' from 'Neutral' and lifted its price target to $1,400 from a previous $960. Analyst Xian Deng attributed the upgrade to better-than-expected clinical data for Vyvgart and an "underappreciated" pipeline beyond the company's lead asset.

The bank's valuation model, which uses a blend of discounted cash flow analysis and peer multiples, suggests that higher projected sales and pipeline contributions will more than compensate for increased near-term spending on selling, general, and administrative expenses.

Vyvgart's Growth Trajectory

The core of the bullish thesis is the massive commercial potential for Vyvgart. UBS raised its probability-adjusted peak sales forecast for the drug to $18 billion, a figure approximately 15% above the market consensus.

Sample IUX Markets – In-articleAd

This optimism is largely driven by recent developments:

  • Myositis Data: Following strong Phase 3 results, UBS now models $5.5 billion in adjusted peak sales for myositis subtypes, more than double the consensus estimate of $2.6 billion. The bank noted a larger addressable patient population and fewer alternative treatments for the condition.
  • Future Indications: The note also expressed bullishness on Vyvgart’s ongoing Phase 3 trial in Sjogren’s disease, with results anticipated in the second half of 2027.

Diversifying Beyond a Single Product

UBS also highlighted Argenx's progress in addressing investor concerns about its reliance on a single product. The analyst expressed "high conviction" in the Phase 3 readout for empasiprubart in multifocal motor neuropathy (MMN), expected in the fourth quarter of 2026.

A successful trial would mark the first launch of a non-Vyvgart drug for Argenx, a key diversification milestone. The report also pointed to the company's recent $2 billion acquisition of Forte, which added an early-stage drug for rare diseases like vitiligo, as another step toward broadening its pipeline.

Read next

More on Stocks
Back to latest news

LATEST